October 2, 2025 — Leads & Copy — Twist Bioscience Corporation (NASDAQ: TWST) announced the publication in Science of the peer-reviewed paper, “Strengthening nucleic acid biosecurity screening against generative protein design tools,” led by Microsoft and co-authored with a consortium of scientific and industry experts including the International Gene Synthesis Consortium.
The publication highlights the importance of iterative improvement, cross industry collaboration and foresight in biosecurity screening. Current biosecurity and screening practices work well to detect and prevent misuse for known proteins and sequences. As AI continues to unlock new possibilities in sequence and protein design, it is important to anticipate and mitigate potential misuse.
Twist’s participation in this initiative exemplifies a proactive approach to safeguard public health. According to Emily M. Leproust, CEO and co-founder of Twist Bioscience, the company has developed and advanced stringent biosecurity screening methods and standards in parallel with commercial offerings since its inception.
Dr. Eric Horvitz, Chief Scientific Officer of Microsoft and co-lead author of the study, stated that as AI opens new frontiers in the life sciences, there is a shared responsibility to continually improve and evolve safety measures.
The study revealed that AI-designed sequences of protein variants of toxins and viral proteins could escape detection by standard biosecurity screening software, leading to improved detection protocols. Twist and its partners used these findings to develop patches and novel strategies that enhance screening accuracy of engineered protein sequences.
At Twist Bioscience, the company works in service of customers who are changing the world for the better. By using their synthetic DNA tools, customers are developing ways to better lives and improve the sustainability of the planet.
For more information about products and services, visit www.twistbioscience.com.
Source: Twist Bioscience Corporation
